Drug Profile
Research programme: erythropoietin gene therapy - Takeda
Alternative Names: AAV-mediated erythropoietin gene therapy - Takeda; Adeno-associated viral vector-mediated erythropoietin gene therapy - TakedaLatest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Class Antianaemics; Gene therapies; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Retinitis pigmentosa
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 08 Nov 2006 Discontinued - Preclinical for Retinal disorders in Italy (unspecified route)
- 08 Nov 2006 Discontinued - Preclinical for Retinal disorders in USA (unspecified route)